Whistleblower Rebuffs Counterclaim for Disclosing Confidential Information
Client Alert | 1 min read | 05.20.16
In U.S. ex rel. Cieszynski v. LifeWatch Servs. (N.D. Ill., May 9), the court dismissed the defendant’s counterclaim against a former employee and FCA whistleblower, ruling that the whistleblower’s disclosure of protected patient information fell within the public policy protections for whistleblowers. As described in a post on the Whistleblower Watch Blog, there has been an increase in recent years of FCA defendants raising counterclaims based on breaches of confidentiality agreements, and this will likely remain an active area of litigation until the courts clearly define what documents an FCA whistleblower can take from an employer and how the whistleblower can use those documents to support FCA allegations.
Contacts
Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 3 min read | 01.21.26
FedRAMP Proposes Updates to Authorization Process—Six New RFCs Released for Public Comment
Client Alert | 3 min read | 01.20.26
DoW Joins SBA’s Fight Against Alleged Pass-Through Fraud in the 8(a) Program
Client Alert | 3 min read | 01.20.26
Federal Government Challenges Minnesota Law Requiring Affirmative Action in State Government



